Transfusion-Transmitted Viruses Study (TTVS)

HLB01910909a

TTVS

(NANB-TAH) Natural History Study of Non-A, Non-B Post-Transfusion Hepatitis (NANB-TAH)

TTV

False

False

True

Coded

False

Epidemiology Study

Open BioLINCC Study

Adult

None

2009-10-01

2009-09-03

2023-02-07

1974-1980

DBDR

Transfusion Medicine

HIV-Related

non-COVID

13146

0

Not Applicable (Specimens Only)

Not Applicable (Specimens Only)

No

Yes

Yes

Yes

Consent for both genetic and non-genetic use of biospecimens is restricted to studies involving transfusion safety.

NANB Hepatitis

To establish a repository of specimens collected from prospectively identified cases of non-A, non-B (NANB) hepatitis after blood transfusion. The major intentions were to determine the incidence of that occurrence, identify the characteristics of the donors associated with the event, and have a resource available to compare laboratory donor screening methods during the study and in subsequent years following completion of the study.

From July 1974 through June 1980, the TTVS group prospectively identified cases of NANB hepatitis in a cohort of 1,533 transfused patients hospitalized short-term for various routine operative procedures. The TTVS collection has been used in a variety of studies, such as the evaluation and validation of Hepatitis C Virus (HCV) immunoassays in screening blood donors (1). In addition, specimens have been requested to evaluate poorly characterized hepatotropic viruses, transmissibility of new viruses (hepatitis G, HHV-8) by transfusion, and the dynamics of HBV/HCV viral replication and seroconversion in recipients.

Serum specimens from 5,655 blood donors were collected from 4 participating blood centers distributed across the US. 3,121 patients were consented to participate in a study of viral hepatitis after blood transfusion. The majority of patients were scheduled for elective surgery. Of these subjects, 1,533 subsequently received blood transfusions. Both transfusion recipients and control subjects that did not require transfusion were observed and blood was collected prior to surgery or pre-transfusion and again during visits at 2-3 week intervals during the first 6 months following the transfusion episode and again between 8-10 months.

A subset of this cohort was subsequently recruited into the Natural History Study of Non-A, Non-B Post Transfusion Hepatitis (NANB-TAH) that also has data and biospecimens available. Subjects cannot be linked between these two studies.

The collection originally consisted of aliquots of serum acquired at patient observation visits and from the collection agency for every donor to each TTVS recipient. These sera included the pre-transfusion or pre-surgical specimen, all interval blood draws from these patients and the non-transfused control patients, a specimen from the donor at the time of blood collection and in a subpopulation of donors a follow-up specimen from donors implicated in suspected cases of transfusion transmitted hepatitis and a matched set of non-implicated donors.

The TTVS collection provides sera from a large transfusion donor-recipient study in which an untransfused control population with reasonably matched characteristics and of adequate size is available.

1. Mosley JW, et al. (1990) Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 263(1):77-78.

Plasma or Serum
Serum